ArticleLeukemia2014
VPREB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia.
Open access · bronzeAbstract readLetter
In one paragraph
Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab.Journal of hematology & oncology · 2025Trial
- Article
- RAG-mediated structural variation and its impact on relapse risk in acute lymphoblastic leukemia.medRxiv : the preprint server for health sciences · 2026Article
- A multiomic characterization of the leukemia cell line REH using short- and long-read sequencing.Life science alliance · 2024Article
- Glucocorticoids paradoxically promote steroid resistance in B cell acute lymphoblastic leukemia through CXCR4/PLC signaling.Nature communications · 2024Article
- Optical Genome Mapping Reveals and Characterizes Recurrent Aberrations and New Fusion Genes in Adult ALL.Genes · 2023Article
- C/EBPβ induces B-cell acute lymphoblastic leukemia and cooperates with BLNK mutations.Cancer science · 2021Article
- An in-depth analysis reveals two new genetic variants on 22q11.2 associated with vitiligo in the Chinese Han population.Molecular biology reports · 2021Article
- Complex karyotype with crypticOncology letters · 2020Article
- Identification of recurrent noncoding mutations in B-cell lymphoma using capture Hi-C.Blood advances · 2019Article
- Autoimmunity checkpoints as therapeutic targets in B cell malignancies.Nature reviews. Cancer · 2018Review
- Article
- Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.Nature genetics · 2015Article
- Review
- Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.Blood · 2015Review
- The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing.Human mutation · 2015Article
- ZNF423 and ZNF521: EBF1 Antagonists of Potential Relevance in B-Lymphoid Malignancies.BioMed research international · 2015Review
- Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia.Genes & development · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 11 institutions in 1 country.
D S MangumDepartment of Pediatrics, University of Utah, Salt Lake City, UT, USA.
J DownieDepartment of Oncological Sciences, Center for Children's Cancer Research, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
C C MasonDepartment of Oncological Sciences, Center for Children's Cancer Research, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
M S JahromiUniversity of Miami School of Medicine, Miami, FL, USA.
D JoshiUniversity of Minnesota School of Pharmacy, Twin Cities, MN, USA.
V RodicDepartment of Pathology, University of Utah, Salt Lake City, UT, USA.
M MüschenDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
N MeekerMountain States Tumor Institute, St Luke's Regional Medical Center, Boise, ID, USA.
N Trede1] Department of Pediatrics, University of Utah, Salt Lake City, UT, USA [2] Department of Oncological Sciences, Center for Children's Cancer Research, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
J K FrazerDepartment of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Y ZhouDepartment of Bioinformatics, St Jude Children's Research Hospital, Memphis, TN, USA.
C ChengDepartment of Bioinformatics, St Jude Children's Research Hospital, Memphis, TN, USA.
S JehaDepartment of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
C-H PuiDepartment of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
C L WillmanDepartment of Pathology, University of New Mexico Cancer Center, University of New Mexico, Albuquerque, NM, USA.
R C HarveyDepartment of Pathology, University of New Mexico Cancer Center, University of New Mexico, Albuquerque, NM, USA.
S P HungerDepartment of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO, USA.
J J YangDepartment of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA.
P Barnette1] Department of Pediatrics, University of Utah, Salt Lake City, UT, USA [2] Department of Oncological Sciences, Center for Children's Cancer Research, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
C G MullighanDepartment of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.
R R MilesDepartment of Pathology, University of Utah, Salt Lake City, UT, USA.
J D Schiffman1] Department of Pediatrics, University of Utah, Salt Lake City, UT, USA [2] Department of Oncological Sciences, Center for Children's Cancer Research, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
St. Jude Children's Research Hospital · USHuntsman Cancer Institute · USUniversity of Utah · USNew Mexico Cancer Center · USRegional Medical Center · USTwin Cities Orthopedics · USUniversity of California, San Francisco · USUniversity of Colorado Denver · USUniversity of Miami · USUniversity of New Mexico · USUniversity of Oklahoma Health Sciences Center · US
Funding
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5MViral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MChildren's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ANDERSON, JAMES R · 2003 to 2013
$67.5MSupport for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5MTargeted activation of autoimmune checkpoints in B cell malignanciesR01CA157644 · NCI · YALE UNIVERSITY · PI Markus Müschen · 2011 to 2026
$5.7MPRE-B CELL RECEPTOR SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIAR01CA137060 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MÜSCHEN, MARKUS · 2009 to 2016
$2.7MNegative feedback signaling in tyrosine kinase-driven leukemiaR01CA172558 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MÜSCHEN, MARKUS · 2013 to 2015
$972kTargeting BCL6 in tyrosine kinase-driven leukemiaR01CA169458 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MÜSCHEN, MARKUS · 2013 to 2015
$972kNCI NIH HHS CA98543NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA137060NCI NIH HHS R01 CA157644NCI NIH HHS R01 CA169458NCI NIH HHS R01 CA172558NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA98413NCI NIH HHS U24 CA114766Wellcome Trust
Abstract
PubMed holds no abstract for this paper.
Indexed as
HumansImmunoglobulin lambda-ChainsImmunoglobulin Light Chains, SurrogatePrecursor Cell Lymphoblastic Leukemia-LymphomaImmunoglobulin lambda-ChainsImmunoglobulin Light Chains, SurrogateVPREB1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.